Phenacetin

Summary

Phenacetin (CHEMBL16073) is an approved small-molecule non-narcotic analgesic (ATC N02BE53); indicated across 2 conditions.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N02BE53 (+2 more)
• Indications: 2 conditions
• Chemistry: 179.22 Da · C10H13NO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL16073
Name	Phenacetin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4754
ChEBI	CHEBI:8050
ATC	N02BE53, N02BE03, N02BE73
Molecular formula	C10H13NO2
Molecular weight	179.22
InChIKey	CPJSUEIXXCENMM-UHFFFAOYSA-N

SMILES: CCOC1=CC=C(C=C1)NC(=O)C

IUPAC name: N-(4-ethoxyphenyl)acetamide

ChEBI definition: A member of the class of acetamides that is acetamide in which one of the hydrogens attached to the nitrogen is substituted by a 4-ethoxyphenyl group.

Pharmacological roles (ChEBI): non-narcotic analgesic, peripheral nervous system drug, cyclooxygenase 3 inhibitor.

Also known as: Fenacetina, Fenidina, Kalmin, NSC-7651, P-acetophenetidide, Phenacetin, Phenacetin melting point standard, Phenacetine, Phenacetinum, Phenazetin, Fenacetin, Acetophenetidin

Parent form; salt/anhydrous children: CHEMBL461346

Patent coverage: 6,610 distinct patent families (21,450 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Prelamin-A/C, Menin/Histone-lysine N-methyltransferase MLL, Cytochrome P450 1A2.

Bioactivity

ChEMBL activities: 7 potent at pChembl ≥ 5 of 9 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CYP1A2	8.31	IC50	4.9	nM	CHEMBL_ACT_24822371
CYP1A2	8.3	IC50	5	nM	CHEMBL_ACT_25593403
CYP1A2	7.92	IC50	12	nM	CHEMBL_ACT_26109716
CYP1A2	7.39	IC50	41	nM	CHEMBL_ACT_25502125
CYP1A2	7.28	IC50	52.4	nM	CHEMBL_ACT_24740401
MEN1	5	Potency	10000	nM	CHEMBL_ACT_4560732
CYP1A2	5	AC50	10000	nM	CHEMBL_ACT_6029818

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).